Jun. 25 at 9:29 PM
Genvor Inc. (OTCQB:
$GNVR ) names Sri Varsha Kodiparthi Bioinformatics Data Scientist, deepening the genomic and computational work behind its BioCypher peptide platform.
Genvor, Inc. (OTCQB: GNVR) has added Sri Varsha Kodiparthi as Bioinformatics Data Scientist, expanding the computational and genomic capability behind the BioCypher platform at the core of its agriculture and human health and wellness programs.
Genvor, Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor.
Kodiparthi brings expertise in genomics, next-generation sequencing, machine learning, and computational biology, with a research background spanning agricultural and biomedical science. Her work supports the genomic analysis and pipeline development that drive Genvor’s AI-accelerated peptide discovery, from sequence design through commercialization-ready candidates.
• Brings hands-on experience in next-generation sequencing, machine learning, and computational biology across academic and industry settings
• Holds a master’s degree in bioinformatics from the University of Texas at El Paso, bridging agricultural and biomedical science
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Through its technology platforms and future partnerships, Genvor intends to advance a new era of natural, science-based innovation.
Genvor is led by Chief Executive Officer Chad Pawlak, Sr. and Chief Financial Officer Don Kalkofen, with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. Learn more at www.genvor.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
$EVGN $PTN $RKDA $DYAI